ENVBHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 31 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Enveric Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ENVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 30 Jan 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 June 2022 | Alliance Global Partners | Initiates | Buy | $1.25 |
| 8 Mar 2022 | Aegis Capital | Downgrade | Hold | $7.00 → $0.20 |
| 8 July 2021 | Aegis Capital | Initiates | Buy | — |
| 28 June 2021 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ENVB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Enveric Biosciences, Inc. returned −76.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 78% of US stocks
Cheaper than 61% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 8% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enveric Biosciences, Inc. has a market value of $6.4M and an enterprise value of −$1.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.7M.
Free cash flow in the twelve months to 30 June 2026: −$8.6M.
Trailing P/E: 0.0×; forward P/E: −1.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Enveric Biosciences, Inc. employs 5 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Enveric Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Enveric Biosciences announced positive results from recently completed IND-enabling in vitro ADMET studies for its lead candidate, EB-003, described as a non-hallucinogenic neuroplastogenic small molecule.
Why it matters — The update concerns preclinical development of Enveric’s lead candidate and its progress through IND-enabling studies.
Enveric Biosciences announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hallucinogenic mescaline derivatives.
Why it matters — A U.S. patent allowance strengthens Enveric's intellectual property protection for its next-generation neuroplastogenic drug candidates in the EVM401 Series.
Enveric Biosciences announced that its CEO, Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, in New York City. The presentation will be prerecorded.
Why it matters — The conference appearance offers Enveric a platform to present its neuroplastogenic therapeutic programs to the investment community.
Enveric Biosciences reported its financial results for the second quarter ended June 30, 2026, and provided a comprehensive corporate update. The company's CEO highlighted important progress made during the quarter on activities supporting its planned first-in-human clinical trial of its next-generation neuroplastogenic small molecules.
Why it matters — An Enveric watcher would care because the corporate update signals continued advancement of the company's pipeline toward a key first-in-human clinical milestone.
Enveric Biosciences announced new preclinical data confirming that its lead psychiatric candidate, EB-003, maintains a non-hallucinogenic profile.
Why it matters — The data strengthens the differentiation of Enveric's lead candidate, which could be important for investors tracking its progress toward potential psychiatric treatments without hallucinogenic side effects.
Of the 1 analysts covering Enveric Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enveric Biosciences, Inc. 18 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Enveric Biosciences, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No analyst covering Enveric Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENVB are extrapolating price history, which says nothing about the business.
Enveric Biosciences, Inc. returned -76.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders.
The most recent item we track (Business Wire, 21 Oct 2026): "Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies". Enveric Biosciences announced positive results from recently completed IND-enabling in vitro ADMET studies for its lead candidate, EB-003, described as a non-hallucinogenic neuroplastogenic small molecule.
Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.
CEO Dr. Joseph Edward Tucker Ph.D. · 5 employees · United States · https://www.enveric.com
